Please find the attached intimation under Regulation 31A (10)(ii) of SEBI listing Regulations 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals has informed BSE that 12 existing members of the promoter and promoter group, collectively holding about 5.10% of the company, will be reclassified as public shareholders. The biggest among them is Sadhanala Venkata Rao at 4.32%, followed by Padmaja Kalyani Sadhanala at 0.54% and Pilli Meena Kumari at 0.16%. This reclassification follows the completion of an open offer on September 23, 2025, by Dr. Shankarappa Nagaraja Vinaya Babu (Acquirer) along with Tumkur Trade Center Private Limited (PAC). The Acquirer and PAC will now be classified as the new promoters of the company. The company has confirmed it meets minimum public shareholding norms, its shares are not suspended, and it has no outstanding dues to SEBI or stock exchanges.
This marks a change of control at Pharmaids Pharmaceuticals, with a new promoter group taking over and the old promoters moving to the public category. Shareholders should expect shifts in board composition, governance, and potentially in the company's strategic direction going forward.